🇺🇸 FDA
Pipeline program

tasimelteon

VP-VEC-162-1105

Phase 1 small_molecule completed

Quick answer

tasimelteon for Hepatic Impairment is a Phase 1 program (small_molecule) at Vanda Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Vanda Pharmaceuticals
Indication
Hepatic Impairment
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials